Cellectis receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Cellectis SA (CLLS)
Cellectis SA stock price live, this page displays NASDAQ CLLS stock exchange data. View the CLLS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Cellectis SA real time stock price chart below.
What Is the Cellectis SA Stock Price Today?
The Cellectis SA stock price today is 1.550.
What Is the Stock Symbol for Cellectis SA?
The stock symbol for Cellectis SA is "CLLS."
What Stock Exchange Does Cellectis SA Trade On?
Cellectis SA is listed and trades on the NASDAQ stock exchange.
Is Cellectis SA a Good Stock to Buy?
Determining whether Cellectis SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CLLS quote. (ISIN: US15117K1034)
What Is the Cellectis SA Stock Price Today?
The Cellectis SA stock price today is 1.550.
What Is the Stock Symbol for Cellectis SA?
The stock symbol for Cellectis SA is "CLLS."
What Stock Exchange Does Cellectis SA Trade On?
Cellectis SA is listed and trades on the NASDAQ stock exchange.
Is Cellectis SA a Good Stock to Buy?
Determining whether Cellectis SA—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CLLS quote. (ISIN: US15117K1034)
1.550
-0.030(-1.90%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.530
1.580
52 wk Range
1.100
2.960
CLLS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
CLLS is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.5301.580
52 wk Range
1.1002.960
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CLLS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
5.600
Upside
+261.29%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Valuation implies a strong free cash flow yield
Cellectis SA Company Profile
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin’s lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.V., as well as with AstraZeneca Ireland Limited. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Cellectis SA SWOT Analysis
Pioneering Gene Therapy | Cellectis leads in allogeneic CAR T-cell therapies, with UCART22 for B-ALL as its flagship candidate, positioning it at the forefront of cancer treatment innovation |
Strategic Partnerships | AstraZeneca collaboration bolsters Cellectis' financial position, extending cash runway to 2026 and opening doors for up to ten potential new programs |
Clinical Milestones Ahead | Pivotal year expected in 2025 with multiple data readouts, including Phase 1 results for UCART22 and UCART20x22, potentially reshaping company's trajectory |
Market Valuation Insights | Analyst price targets range from $3 to $11 per share, with the stock currently trading below estimated fair value, suggesting potential upside for investors |
Cellectis SA Earnings Call Summary for Q3/2024
- Cash reserves increased to $264M, bolstered by $140M AstraZeneca investment and $47M collaboration funding
- Three new R&D programs initiated with AstraZeneca, including two allogeneic CAR T therapies and an in vivo gene therapy
- UCART123 program deprioritized; focus shifted to BALLI-01 study and other promising assets
- Company aims to extend cash runway to 2027 through financial management and partnership milestones
- Phase I data presentation planned for 2025; strong patient demand noted for UCART20x22 program
Last Updated: 07/11/2024, 06:10 am
Read Full TranscriptCompare CLLS to Peers and Sector
Metrics to compare | CLLS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCLLSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.8x | −0.1x | −0.5x | |
PEG Ratio | −0.03 | −0.01 | 0.00 | |
Price/Book | 0.9x | 3.0x | 2.6x | |
Price / LTM Sales | 2.0x | 3.4x | 3.0x | |
Upside (Analyst Target) | 220.3% | 22.3% | 54.7% | |
Fair Value Upside | Unlock | −3.6% | 8.4% | Unlock |
Analyst Ratings
4 Buy
1 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 5.600
(+261.29% Upside)
Earnings
Latest Release
May 13, 2025
EPS / Forecast
-0.17 / -0.24
Revenue / Forecast
12.00M / 11.96M
People Also Watch
FAQ
What Is the Cellectis (CLLS) Stock Price Today?
The Cellectis stock price today is 1.55
What Stock Exchange Does Cellectis Trade On?
Cellectis is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Cellectis?
The stock symbol for Cellectis is "CLLS."
What Is the Cellectis Market Cap?
As of today, Cellectis market cap is 109.53M.
What Is Cellectis's Earnings Per Share (TTM)?
The Cellectis EPS (TTM) is -0.62.
When Is the Next Cellectis Earnings Date?
Cellectis will release its next earnings report on 30 July 2025.
From a Technical Analysis Perspective, Is CLLS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.